Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

Progress of Phase I Programme With Oral Iclaprim "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of

First Modules due Before Year-end 2007

REINACH, Switzerland, December 12 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the enrolment and dosing of the first patients in the Phase II clinical study with intravenous iclaprim in the treatment of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) / healthcare-associated pneumonia (HCAP).

In addition, Arpida announced results of a Phase I study with oral iclaprim. The primary aim of the study was to assess the safety and tolerability of single ascending doses of an oral capsule formulation of iclaprim in healthy volunteers.

Moreover, Arpida today announced that the first modules of the New Drug Application (NDA) for intravenous iclaprim in its first indication, cSSSI, are ready and will be filed before year-end 2007. The filing of the NDA package is expected to be completed by the end of February 2008.

First patients enrolled in Phase II trial with intravenous iclaprim in HAP/VAP/HCAP

Patient recruitment has started and several additional clinical centres are expected to start recruiting within the next few weeks. The trial remains on track for completion in 2008.

HAP/VAP/HCAP as a potential second indication could substantially enhance iclaprim's prospects as a potent novel therapy against multi-drug resistant bacteria. In the area of pneumonia, the need for new drugs addressing MRSA-infections is particularly pressing.

The Phase II trial is designed as a multi-centre, randomised, double-blind, comparative study. The efficacy and safety of two different dosing regimens of iclaprim will be compared to the current standard of care vancomycin. More than 130 patients will be enrolled. Patients will be treated for 7-14 days and a Test-of-Cure (TOC) visit will be performed 7-14
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... 180 List of Outstanding Issues (LOI) from the European ... (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 ... investigational drug candidate being evaluated for weight loss. ... time point were adequately addressed by the Company based ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... 8, 2010 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... nanotechnology company developing products and licensing opportunities in ... and biotechnology research and development tools businesses, announced ... development and manufacturing agreement with EV Group, a ...
... properties, carbon nanotubes are attractive building blocks ... logic devices, and memory elements. However, ... of individual carbon nanotubes and the nanotube-devices, ... commercial use. Now, researchers at Northwestern ...
... Calif., Dec. 7, 2010 California-based StemCyte, Inc. ... www.StemCyte.com , a comprehensive resource on cord blood ... an effort to provide the most comprehensive source ... StemCyte,s new website includes extensive information for customers, ...
Cached Biology Technology:Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 3Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 4Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 5Using new materials to make more reliable nanoelectromechanical systems 2StemCyte Launches New Website 2
(Date:7/30/2014)... massive collection of 20-million-year-old amber found in the Dominican ... is yielding fresh insights into ancient tropical insects and ... fully curated, a task that will take many years, ... in the world, the researchers report. , Perhaps ... a pygmy locust, a tiny grasshopper the size of ...
(Date:7/30/2014)... use of iodine-125 (125I) in cancer treatment has ... root ganglia are critical for neural transmission between ... Zhang and colleagues from Institute of Radiation Medicine, ... 125I could be implanted into rat dorsal root ... 125I seeds with different radioactivity (0, 14.8, 29.6 ...
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... NEW YORK (July 24, 2009) -- A large attack on ... than a million people, necessitating their treatment with powerful antibiotics. ... to be effective, quick detection and treatment are essential, and ... ill people. The results of a computer simulation study ...
... GALVESTON, Texas Researchers at the University of Texas ... to gain weight while using depot medroxyprogesterone acetate, more commonly ... dispel the myth that all women who use DMPA will ... DMPA users whose weight increased by 5 percent within ...
... Union for the Conservation of Nature (IUCN),s Red List ... of species around the planet, and according to these ... endangered. However, research carried out recently by Jos Luis ... scientific protocol designed to identify threatened plants and animals. ...
Cached Biology News:Early detection and quick response are key to defense against anthrax attack 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2Red List overlooks island species 2Red List overlooks island species 3
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Biology Products: